Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 57 Carcinoma, Hepatocellular 45 Carcinoma, Non-Small-Cell Lung 23 Small Cell Lung Carcinoma 19 Ovarian Neoplasms 18 Colorectal Neoplasms 18 Breast Neoplasms 17 Sarcoma 14 Neoplasms 14 Triple Negative Breast Neoplasms 13 Nasopharyngeal Carcinoma 11 Lung Neoplasms 10 Esophageal Squamous Cell Carcinoma 10 Cholangiocarcinoma 10 Osteosarcoma 9 Esophageal Neoplasms 9 Advanced Gastric Cancer 9 Neoplasm Metastasis 8 Biliary Tract Neoplasms 8 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Recurrence 6 Pancreatic Neoplasms 6 Head and Neck Neoplasms 6 Liver Neoplasms 5 Glioma 5 Thyroid Neoplasms 4 Solid Tumor 4 Melanoma 4 Drug-Related Side Effects and Adverse Reactions 4

Interventions

Etoposide 3 Carboplatin 3 Paclitaxel 2 sintilimab 1 pembrolizumab 1 olaparib 1 ceralasertib 1 atezolizumab 1 apatinib 1 anlotinib 1 Topotecan 1 Platinum 1 Immune Checkpoint Inhibitors 1 Drug Therapy 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC × apatinib × Clear all

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡